canine osteosarcoma Archives - Page 2 of 2

ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs

Ten sites now participating in trial of alternative treatment to chemotherapy for canine osteosarcoma Olathe, Kansas, Nov. 12, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces that 10 investigation sites across the U.S. are now participating in the pivotal trial of ELIAS cancer immunotherapy (ECI®). This marks an expansion of the study ELIAS initiated in May to pursue licensure of ECI treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. The geographical areas served by the clinical trial investigation sites include Southern California, the Intermountain Region, the Desert Southwest, the Chicago metropolitan area, North Texas, the Carolinas, and the Mid-Atlantic region, which includes Southeast Pennsylvania, Virginia and Washington D.C. ELIAS will continue recruiting sites to further expand pet owner access to the trial. To learn more about participating [...]

By Jessica Wiley|2022-01-08T14:27:21-06:00November 12th, 2020|Categories: News, Press Releases|Tags: canine osteosarcoma, clinical trial|0 Comments

Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy

Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience survival times twice that of amputation alone. Median survival time for dogs in the study was 415 days, with one dog developing metastasis then experiencing spontaneous complete remission. Read the full study results. In May, ELIAS Animal Health announced the initiation of a follow-up study to pursue licensure of ECI [...]

By Jessica Wiley|2020-07-27T10:26:01-06:00July 14th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial, results, university of missouri|0 Comments

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin, a type of chemotherapy. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment [...]

By Jessica Wiley|2020-06-16T10:15:26-06:00May 28th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial|0 Comments

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]

By Jessica Wiley|2023-01-06T15:41:25-06:00May 5th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial, translational medicine|0 Comments

ELIAS Animal Health announces new additions to leadership team ahead of clinical study launch

Olathe, Kan., February 26, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced today the appointment of Evan Courtemanche as Vice President of Manufacturing, and Jody Ehrhardt, as Director of Clinical Studies. Evan Courtemanche brings an extensive background in mammalian cell-culture manufacturing and supply chain functions in FDA and USDA-regulated therapeutics, and managing contract manufacturing relationships, both international and domestic. He currently oversees the biologics manufacturing processes and facility where the company’s USDA-regulated cancer immunotherapy is manufactured. Previously, Mr. Courtemanche served in manufacturing leadership and oversight roles for Aratana Therapeutics and Genzyme. Jody Ehrhardt, CCRC, brings more than 25 years of experience in clinical studies in both human and animal sciences. As the Director of Clinical Studies for ELIAS, she manages clinical study development, including protocol composition, study site recruitment and management, and regulatory reporting. Previously, she served as a [...]

By Jessica Wiley|2024-04-30T11:50:03-06:00February 26th, 2020|Categories: News|Tags: canine osteosarcoma, clinical trial|0 Comments

Companion animal access to immunotherapy treatments trails human medicine

Immunotherapy treatments are a hot topic in the area of treating human malignancies, which begs the question in the minds of many pet owners whose dogs or cats are diagnosed with cancer: where are these therapies for the four-legged members of the family? There are several barriers to making immunotherapies available in the veterinary space. However, a recent article in Veterinary Practice News by Hans Klingemann, MD, PhD, details some of these challenges and highlights the work being done by ELIAS Animal Health to overcome such barriers. “While patient survival outcomes using traditional cancer therapies such as chemotherapy and radiation have not significantly changed in the past couple of decades, they still remain the proven standard of care used by veterinary oncologists,” said Noe Reyes, Chief Medical Officer for ELIAS. “There is a significant unmet need for safer and more effective therapies to treat cancer. Immunotherapies, including adoptive T cell [...]

By Jessica Wiley|2022-08-04T18:47:53-06:00May 14th, 2019|Categories: Blog|Tags: autologous prescription product, cancer immunotherapy, canine osteosarcoma|0 Comments

University announces advancement in canine cancer treatment

The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.

By Jessica Wiley|2020-02-26T15:08:42-06:00March 3rd, 2019|Categories: News|Tags: cancer immunotherapy, canine cancer, canine osteosarcoma, university of missouri|0 Comments

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ELIAS Cancer Immunotherapy (ECI®) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]

By Jessica Wiley|2022-08-04T18:47:03-06:00October 25th, 2018|Categories: Press Releases|Tags: canine cancer, canine osteosarcoma, results|0 Comments